CLDX
Celldex Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$38.24
−1.90%Year over year
Reported trailing growth
- Revenue
- -98.1%
- EBITDA
- -38.1%
- EBIT
- -38.8%
- EPS
- -44.9%
- Free cash flow
- -29.1%
- Operating cash flow
- -26.5%
Forward estimates
Based on analyst estimates
- Revenue
- +2063.0%
- EBITDA
- -3.6%
- EPS
- +8.3%
Three-year CAGR
- Revenue
- -14.0%
- EBITDA
- -65.1%
- EBIT
- -47.3%
- Net income
- -63.9%
- EPS
- -59.2%
- Free cash flow
- -33.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026